lilly retatrutide trial Eli just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Eli Lilly stock jumps on

If you microdose retatrutide and lose the glucagon component, you might go from 24% weight loss to 15% weight loss, essentially converting your triple agonist into a less efficient version of what you could get from semaglutide alone

Their Semaglutide injections in Jupiter finally made weight loss feel doable

100+ biomarkers, physician-interpreted results, and a clear protocol for what comes next.

Theyd still be losing money, at least in the short term

The ingredients in Activate, particularly the combination of hibiscus and lemon verbena polyphenols, have been shown in clinical studies to modestly increase GLP-1 levels (12-22% above baseline)

One AssuredPartners case study found GLP1 users saved about $560 per person per year in medical costs but against an average annual drug cost of $6,540, the nearterm ROI is negative for most employers